These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26837602)

  • 21. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
    Constenla D; Liu T
    Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of adult vaccinations: A systematic review.
    Leidner AJ; Murthy N; Chesson HW; Biggerstaff M; Stoecker C; Harris AM; Acosta A; Dooling K; Bridges CB
    Vaccine; 2019 Jan; 37(2):226-234. PubMed ID: 30527660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination.
    Che D; Zhou H; He J; Wu B
    BMC Health Serv Res; 2014 Feb; 14():56. PubMed ID: 24507480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
    Mahumud RA; Alam K; Keramat SA; Ormsby GM; Dunn J; Gow J
    PLoS One; 2020; 15(6):e0233499. PubMed ID: 32484811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines.
    De la Hoz-Restrepo F; Castañeda-Orjuela C; Paternina A; Alvis-Guzman N
    Vaccine; 2013 Jul; 31 Suppl 3():C80-7. PubMed ID: 23777697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50-64 years old.
    Raj SM; Chughtai AA; Sharma A; Tan TC; MacIntyre CR
    Vaccine; 2019 Sep; 37(40):5979-5985. PubMed ID: 31473001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland.
    Ess SM; Schaad UB; Gervaix A; Pinösch S; Szucs TD
    Vaccine; 2003 Jul; 21(23):3273-81. PubMed ID: 12804858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunisation schedule of the Spanish Association of Paediatrics: 2013 recommendations].
    Moreno-Pérez D; Álvarez García FJ; Arístegui Fernández J; Barrio Corrales F; Cilleruelo Ortega MJ; Corretger Rauet JM; González-Hachero J; Hernández-Sampelayo Matos T; Merino Moína M; Ortigosa Del Castillo L; Ruiz-Contreras J;
    An Pediatr (Barc); 2013 Jan; 78(1):59.e1-27. PubMed ID: 23228438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic value of influenza vaccination.
    de Waure C; Veneziano MA; Cadeddu C; Capizzi S; Specchia ML; Capri S; Ricciardi W
    Hum Vaccin Immunother; 2012 Jan; 8(1):119-29. PubMed ID: 22251999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
    Boonacker CW; Broos PH; Sanders EA; Schilder AG; Rovers MM
    Pharmacoeconomics; 2011 Mar; 29(3):199-211. PubMed ID: 21250759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
    Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK
    Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used.
    Nymark LS; Sharma T; Miller A; Enemark U; Griffiths UK
    Vaccine; 2017 Dec; 35(49 Pt B):6828-6841. PubMed ID: 29146380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children.
    Falcón-Lezama JA; Saucedo-Martínez R; Betancourt-Cravioto M; Alfaro-Cortes MM; Bahena-González RI; Tapia-Conyer R
    BMC Infect Dis; 2020 Mar; 20(1):240. PubMed ID: 32197591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
    Allsup S; Gosney M; Haycox A; Regan M
    Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluations of childhood influenza vaccination: a critical review.
    Newall AT; Jit M; Beutels P
    Pharmacoeconomics; 2012 Aug; 30(8):647-60. PubMed ID: 22788257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.